SecBot SecBot
SECBOTREPLAY Home › Report › ANIP

ANIP · ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN…

ANI Pharmaceuticals, Inc. · PRESS-RELEASE filed Jul 13, 2026 at 06:50 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 13, 2026 at 06:50 ET

ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the posterior segment (NIU-PS), meeting both co-primary endpoints with statistical significance. The results support the drug's safety and efficacy in a real-world setting, potentially boosting commercial uptake.

  • SYNCHRONICITY trial met co-primary endpoints: mean change in BCVA (+3.6 letters, p<0.0077) and CST (-157.5 microns, p<0.0001) at 6 months.
  • Safety profile consistent with prior ILUVIEN trials; 29% treatment-related TEAEs, most common ocular hypertension (6%) and cataract (5%).
  • ILUVIEN already FDA-approved for DME (2014) and expanded for chronic NIU-PS (2025); this Phase 4 data adds real-world evidence.
  • Detailed results to be presented at medical conferences in Q4 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access